Proprietary Technology & Business ModelOwning a proprietary mucoadhesive oral film platform and a partnership/licensing strategy supports scalable commercialization without requiring full-build commercial infrastructure. This durable model can generate recurring licensing revenue, reduce capex needs, and enable faster market entry through partners.

Revenue Rebound And Improving Gross MarginA sustained revenue rebound and materially higher gross margin signal improving product traction or better pricing/production economics. If maintained, this trend supports future operating leverage, reduces the gap to profitability, and validates the commercial appeal of the company’s offerings over the medium term.

Elimination Of Reported DebtRemoving debt materially lowers solvency risk and interest obligations, preserving cash for R&D or strategic initiatives. The shift from high leverage to zero debt improves funding optionality and reduces bankruptcy risk, making the balance sheet structurally more resilient to ongoing investment cycles.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow of this magnitude indicates the business is not self-funding and must access external capital repeatedly. Over the medium term, persistent burn pressures leverage, dilutes shareholders through financing, and constrains the company’s ability to scale without new funds.

Deep And Recurring Net LossesVery large and recurring operating losses signal the cost base far exceeds current revenue scale. This structural deficit suggests the business remains in an intensive development phase and faces a prolonged path to profitability unless revenues scale substantially or operating costs are materially reduced.

Thin Equity Buffer Versus AssetsA small equity base relative to assets leaves limited capitalization cushion against ongoing losses and increases dependence on external financing. Structurally, this raises dilution and refinancing risk over months, and reduces flexibility to absorb operational setbacks or execute large strategic investments.

KLAR FAQ

What was Klaria Pharma Holding AB’s price range in the past 12 months?

Klaria Pharma Holding AB lowest stock price was kr0.39 and its highest was kr1.72 in the past 12 months.

What is Klaria Pharma Holding AB’s market cap?

Klaria Pharma Holding AB’s market cap is kr202.68M.

When is Klaria Pharma Holding AB’s upcoming earnings report date?

Klaria Pharma Holding AB’s upcoming earnings report date is Feb 20, 2026 which is in 3 days.

How were Klaria Pharma Holding AB’s earnings last quarter?

Klaria Pharma Holding AB released its earnings results on Nov 26, 2025. The company reported -kr0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.04.

Is Klaria Pharma Holding AB overvalued?

According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Klaria Pharma Holding AB pay dividends?

Klaria Pharma Holding AB does not currently pay dividends.

What is Klaria Pharma Holding AB’s EPS estimate?

Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Klaria Pharma Holding AB have?

Klaria Pharma Holding AB has 245,976,150 shares outstanding.

What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?

Klaria Pharma Holding AB reported an EPS of -kr0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.859%.

Which hedge fund is a major shareholder of Klaria Pharma Holding AB?

Currently, no hedge funds are holding shares in SE:KLAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Klaria Pharma Holding AB

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.